Skip to main content

Table 2 Ongoing clinical trials studying anti-IL-1β strategies, alone or in combination, for lung cancer treatment

From: Targeting interleukin-1β and inflammation in lung cancer

Therapy

Target

Tumor type

Recruitment status

Study type

ClinicalTrials.gov identifier

Trial name

Start date

Estimated completion date

Canakinumab + pembrolizumab + chemotherapy

IL-1β + PD-1

NSCLC

Active, not recruiting

Phase III

NCT03631199 [66]

CANOPY-1

December 2018

September 2022

Canakinumab + chemotherapy

IL-1β

NSCLC

Active, not recruiting

Phase III

NCT03626545 [67]

CANOPY-2

January 2019

March 2022

Canakinumab +/− pembrolizumab

IL-1β +/− PD-1

NSCLC

Recruiting

Phase II

NCT03968419 [68]

CANOPY-N

November 2019

January 2022

Canakinumab

IL-1β

NSCLC

Recruiting

Phase III

NCT03447769 [69]

CANOPY-A

March 2018

January 2027

Canakinumab +/− PDR001

IL-1β +/− PD-1

NSCLC, TNBC, CRC

Active, not recruiting

Phase Ib

NCT02900664 [70]

August 2016

March 2021

Canakinumab + PDR001 + chemotherapy

IL-1β +/− PD-1

NSCLC

Active, not recruiting

Phase Ib

NCT03064854 [71]

ElevatION:NSCLC-101

May 2017

December 2021

  1. Abbreviations: CRC colorectal cancer, IL-1β interleukin-1beta, NSCLC non-small cell lung cancer, PD-1 programmed death-1, PDR001 PD-1 inhibitor, aka spartalizumab, TNBC triple negative breast cancer